Please assess the completion status of the following clinical trial:

Trial Title: Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria for participants enrolling into Cohort 1:~* Study participants had documented persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix~* Study participants had not been treated with systemic chemotherapy and were not amenable to curative treatment~* Prior radiation with or without radio-sensitizing chemotherapy was allowed~* Inclusion Criteria for participants enrolling into Cohort 2:~* Participants had documented evidence of cervical adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma International Federation of Gynecology and Obstetrics (FIGO) 2018 Stages 1B2 to 4A~* Participants had not received prior chemotherapy or radiotherapy for cervical cancer~* Inclusion Criteria for all participants:~* Archival tumor tissue sample or newly obtained core or excisional biopsy was required~* Participants who had Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 to 1 were eligible~* Participants had a life expectancy greater than or equal to 12 weeks~* Participants had adequate hematological, hepatic, renal, and coagulation function as defined in the protocol~* Participants with known Human immunodeficiency virus (HIV) infections were eligible if the criteria described in the protocol were met~* Participants with Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) infections were eligible if the criteria described in the protocol were met~* Other protocol defined inclusion criteria could apply~Exclusion Criteria:~* Exclusion Criteria for All Participants were:~* Participants with active central nervous system (CNS) metastases causing clinical symptoms or metastases that required therapeutic intervention were excluded. Participants with a history of treated CNS metastases (by surgery or radiation therapy) were not eligible unless they had fully recovered from treatment, demonstrated no progression for at least 4 weeks, and were not using steroids for at least 7 days prior to the start of study intervention~* Participants that received any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that did not require immuno-suppression~* Participants with significant acute or chronic infections~* Participants with active autoimmune disease that might have deteriorated when receiving an immuno-stimulatory agent~* Participants with clinically significant cardiovascular/cerebrovascular disease including: a cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, or serious cardiac arrhythmia~* Participants with a history of bleeding diathesis or recent major bleeding events~* Participant that had received prior cancer treatment with any other immunotherapy or checkpoint inhibitors or any other immune-modulating monoclonal antibody (mAb)~* Exclusion Criteria for Participants in Cohort 1A related to use of bevacizumab were:~* Participants with inadequately controlled hypertension~* Prior history of hypertensive crisis or hypertensive encephalopathy~* Participants with significant vascular disease within 6 months prior to Screening~* Participants with a history of hemoptysis within 1 month prior to Screening~* Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab~* Participants with a history of abdominal or trache-oesophageal fistula or gastrointestinal (GI) perforation within 6 months prior to Screening~* Participants with clinical signs of GI obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding~* Participants with evidence of abdominal free air not explained by paracentesis or recent surgical procedure~* Participants with serious, non-healing wound, active ulcer, or untreated bone fracture~* Participants with proteinuria~* Other protocol defined exclusion criteria could apply

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1A:M7824+Cisplatin/Carboplatin+Paclitaxel+Bevacizumab (Type: EXPERIMENTAL): None
- Cohort1B:M7824+Cisplatin or Carboplatin+Paclitaxel (Type: EXPERIMENTAL): None
- Cohort 2: M7824+Cisplatin+ Radiotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete